加兰他胺与脑卒中后认知障碍的认知康复相结合:一项概念验证研究
Mélanie Planton1,2, Federico Nemmi2, Berengère Pages1
1Department of Neurology, Toulouse University Hospital, Toulouse, France.
Brain injury
|October 3, 2024
目的:
我们开展了一项概念验证研究,以评估卒中后联合认知康复(CR)治疗时,加兰他敏治疗与安慰剂相比的效果。
材料与方法:
在一项为期12周的双盲、随机、对照试验中,患者被分配至加兰他敏联合认知康复组(G-CR)或安慰剂联合认知康复组(P-CR)。主要结局指标为在12周时从血管性认知障碍(VCD)转归为非血管性认知障碍(no-VCD)的患者比例。次要结局指标包括认知、情绪、生活质量以及N-背侧fMRI范式,在基线、6周和12周以及经过8周洗脱期后进行评估。
结果:
十名患者被分配至G-RC组,十二名患者被分配至P-RC组。经过12周后,所有患者中有40.1%转为无VCD状态,且两组间比例相似。两组患者在认知康复治疗6周后,均显示出情景记忆和工作记忆、执行功能以及生活质量的改善。抑郁和焦虑程度有所降低,且所有获益在洗脱期后仍持续存在。在右侧顶叶小叶观察到一种交互效应N-back 任务。
结论:
干预措施可改善认知功能并引起明显的大脑皮层重组,但尚无法建立神经变化与行为测量指标之间的相关性。
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Parkinson's Disease: Treatment
233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233


